A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia

Haematologica. 2022 Jun 1;107(6):1454-1459. doi: 10.3324/haematol.2021.280026.

Authors

Milena Kohn¹, Marc Delord², Maureen Chbat¹, Amina Guemriche¹, Fatiha Merabet¹, Anne-Laure Roupie¹, Naelle Lombion³, Hassan Farhat¹, Thomas Longval¹, Aurélie Cabannes-Hamy¹, Juliette Lambert¹, Stéphanie Marque-Juillet⁴, Victoria Raggueneau⁴, Jennifer Osman⁴, Marc Spentchian⁴, Sophie Rigaudeau¹, Philippe Rousselot¹, Caroline Besson⁵

Affiliations

¹ Service d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, 78150.
² DRCI, Centre Hospitalier de Versailles, Le Chesnay, 78150.
³ Service d'hématologie, Hôpital de Poissy, 78300 Poissy.
⁴ Service de Biologie, Centre Hospitalier de Versailles, Le Chesnay, 78150.
⁵ Service d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, 78150, France; UVSQ, Inserm, CESP, 94805, Villejuif. [email protected].

No abstract available

MeSH terms

Antigens, CD20 / genetics
COVID-19*
Humans
Immunoglobulins
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
Leukemia, Lymphocytic, Chronic, B-Cell* / pathology
Lymphoma* / drug therapy
RNA, Messenger
Rituximab / therapeutic use

Substances

Antigens, CD20
Immunoglobulins
RNA, Messenger
Rituximab